Daniel Atwine1,2,3, Maryline Bonnet1,4,3, Anne-Marie Taburet5,6. 1. Epicentre Mbarara Research Centre, Mbarara, Uganda. 2. Mbarara University of Science and Technology, Mbarara, Uganda. 3. University of Montpellier, Montpellier, France. 4. IRD UMI233 TransVIHMI-INSERM U1175, Montpellier, France. 5. Bicetre hospital, Paris, France. 6. UMR 1184, INSERM, CEA, Université Paris-Sud.
Abstract
AIMS: Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and RH interaction in TB/HIV high-burden countries. METHODS: We conducted a systematic review of studies conducted in the high TB/HIV-burden countries between 1990 and 2016 on EFV pharmacokinetics during RH coadministration in coinfected patients. Two reviewers conducted article screening and data collection. RESULTS: Of 119 records retrieved, 22 were included (two conducted in children), reporting either EFV mid-dose or pre-dose concentrations. In 19 studies, median or mean concentrations of RH range between 1000 and 4000 ng ml-1 , the so-called therapeutic range. The proportion of patients with subtherapeutic concentration of RH ranged between 3.1 and 72.2%, in 12 studies including one conducted in children. The proportion of patients with supratherapeutic concentration ranged from 19.6 to 48.0% in six adult studies and one child study. Five of eight studies reported virological suppression >80%. The association between any grade hepatic and central nervous system adverse effects with EFV/RH interaction was demonstrated in two and three studies, respectively. The frequency of the CYP2B6 516G > T polymorphism ranged from 10 to 28% and was associated with higher plasma EFV concentrations, irrespective of ethnicity. CONCLUSIONS: Anti-TB drug coadministration minimally affect the EFV exposure, efficacy and safety among TB-HIV coinfected African and Asian patients. This supports the current 600 mg EFV dosing when coadministered with anti-TB drugs.
AIMS: Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges. We reviewed recent data on EFV and RH interaction in TB/HIV high-burden countries. METHODS: We conducted a systematic review of studies conducted in the high TB/HIV-burden countries between 1990 and 2016 on EFV pharmacokinetics during RH coadministration in coinfected patients. Two reviewers conducted article screening and data collection. RESULTS: Of 119 records retrieved, 22 were included (two conducted in children), reporting either EFV mid-dose or pre-dose concentrations. In 19 studies, median or mean concentrations of RH range between 1000 and 4000 ng ml-1 , the so-called therapeutic range. The proportion of patients with subtherapeutic concentration of RH ranged between 3.1 and 72.2%, in 12 studies including one conducted in children. The proportion of patients with supratherapeutic concentration ranged from 19.6 to 48.0% in six adult studies and one child study. Five of eight studies reported virological suppression >80%. The association between any grade hepatic and central nervous system adverse effects with EFV/RH interaction was demonstrated in two and three studies, respectively. The frequency of the CYP2B6 516G > T polymorphism ranged from 10 to 28% and was associated with higher plasma EFV concentrations, irrespective of ethnicity. CONCLUSIONS: Anti-TB drug coadministration minimally affect the EFV exposure, efficacy and safety among TB-HIV coinfected African and Asian patients. This supports the current 600 mg EFV dosing when coadministered with anti-TB drugs.
Authors: Tanuja N Gengiah; Nicholas H G Holford; Julia H Botha; Andrew L Gray; Kogieleum Naidoo; Salim S Abdool Karim Journal: Eur J Clin Pharmacol Date: 2011-11-23 Impact factor: 2.953
Authors: A Jindani; G Borgulya; I Westermann de Patiño; T Gonzales; R A de Fernandes; B Shrestha; D Atwine; M Bonnet; M Burgos; F Dubash; N Patel; A M Checkley; T S Harrison; D Mitchison Journal: Int J Tuberc Lung Dis Date: 2016-06 Impact factor: 2.373
Authors: M Whirl-Carrillo; E M McDonagh; J M Hebert; L Gong; K Sangkuhl; C F Thorn; R B Altman; T E Klein Journal: Clin Pharmacol Ther Date: 2012-10 Impact factor: 6.875
Authors: Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Nathan Ford; Andrew Ball; Rachel Baggaley; Marco Vitoria; Daniel Low-Beer; Martina Penazzato; Lara Vojnov; Silvia Bertagnolio; Vincent Habiyambere; Meg Doherty; Gottfried Hirnschall Journal: Lancet Infect Dis Date: 2017-10-20 Impact factor: 25.071
Authors: Matthew L Romo; Ellen Brazier; Dominique Mahambou-Nsondé; Reneé De Waal; Christine Sekaggya-Wiltshire; Cleophas Chimbetete; Winnie R Muyindike; Gad Murenzi; Cordelia Kunzekwenyika; Thierry Tiendrebeogo; Josephine A Muhairwe; Patricia Lelo; Anastase Dzudie; Christelle Twizere; Idiovino Rafael; Oliver C Ezechi; Lameck Diero; Marcel Yotebieng; Lukas Fenner; Kara K Wools-Kaloustian; N Sarita Shah; Denis Nash Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Awewura Kwara; Hongmei Yang; Sampson Antwi; Anthony Enimil; Fizza S Gillani; Albert Dompreh; Antoinette Ortsin; Theresa Opoku; Dennis Bosomtwe; Anima Sarfo; Lubbe Wiesner; Jennifer Norman; Wael A Alghamdi; Taimour Langaee; Charles A Peloquin; Michael H Court; David J Greenblatt Journal: Antimicrob Agents Chemother Date: 2018-12-21 Impact factor: 5.191
Authors: C Schlaeppi; F Vanobberghen; G Sikalengo; T R Glass; R C Ndege; G Foe; A Kuemmerle; D H Paris; M Battegay; C Marzolini; M Weisser Journal: HIV Med Date: 2019-09-18 Impact factor: 3.180
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790